The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform

Hisanori Minakami - One of the best experts on this subject based on the ideXlab platform.

  • effect of gonadotropin releasing Hormone Agonist on a uterine arteriovenous malformation
    Obstetrics & Gynecology, 2006
    Co-Authors: Mamoru Morikawa, Takashi Yamada, Hideto Yamada, Hisanori Minakami
    Abstract:

    BACKGROUND: The effect of Gonadotropin-Releasing Hormone Agonist (GnRHa) on uterine arteriovenous malformations (AVM) is not well known. CASE: A 37-year-old woman with a previous cesarean was diagnosed as having a uterine AVM after a spontaneous abortion with massive vaginal bleeding. The AVM decreased in size from 5.1 x 3.8 cm to 1.4 x 1.0 cm after 6 months of therapy with a GnRHa. Uterine artery embolization conducted after the GnRH therapy resulted in complete disappearance of the AVM. The patient's menstrual cycles and ovulation resumed 3 months after uterine artery embolization. CONCLUSION: Gonadotropin-Releasing Hormone Agonist therapy reduced the size of the uterine AVM. Thus, GnRHa therapy may be useful for uterine AVM in situations where uterine artery embolization must be postponed.

  • Effect of Gonadotropin-Releasing Hormone Agonist on a uterine arteriovenous malformation.
    Obstetrics and gynecology, 2006
    Co-Authors: Mamoru Morikawa, Takashi Yamada, Hideto Yamada, Hisanori Minakami
    Abstract:

    The effect of Gonadotropin-Releasing Hormone Agonist (GnRHa) on uterine arteriovenous malformations (AVM) is not well known. A 37-year-old woman with a previous cesarean was diagnosed as having a uterine AVM after a spontaneous abortion with massive vaginal bleeding. The AVM decreased in size from 5.1 x 3.8 cm to 1.4 x 1.0 cm after 6 months of therapy with a GnRHa. Uterine artery embolization conducted after the GnRH therapy resulted in complete disappearance of the AVM. The patient's menstrual cycles and ovulation resumed 3 months after uterine artery embolization. Gonadotropin-Releasing Hormone Agonist therapy reduced the size of the uterine AVM. Thus, GnRHa therapy may be useful for uterine AVM in situations where uterine artery embolization must be postponed.

Bulent Urman - One of the best experts on this subject based on the ideXlab platform.

  • Medical treatment of uterocutaneous fistula with Gonadotropin-Releasing Hormone Agonist administration.
    Obstetrics and gynecology, 2008
    Co-Authors: Ayse Seyhan, Baris Ata, Bilhan Sidal, Bulent Urman
    Abstract:

    Uterocutaneous fistula is a rare complication of uterine surgery. All published cases have been surgically treated with hysterectomy and excision of the fistulous tract. We report a case of uterocutaneous fistula that was successfully treated with Gonadotropin-Releasing Hormone Agonist administration. A 25-year-old woman reported bloody discharge during her periods from a previous Pfannenstiel incision. A fistulous tract leading from the incision scar to the uterus was diagnosed. Leuprolide acetate depot was administered twice subcutaneously at a dose of 11.25 mg. The fistulous tract closed spontaneously, and the patient was symptom free thereafter. Medical treatment with Gonadotropin-Releasing Hormone Agonists should be considered before resorting to surgery for treatment of uterocutaneous fistulae.

  • Medical treatment of uterocutaneous fistula with Gonadotropin-Releasing Hormone Agonist administration.
    Obstetrics & Gynecology, 2008
    Co-Authors: Ayse Seyhan, Baris Ata, Bilhan Sidal, Bulent Urman
    Abstract:

    BACKGROUND: Uterocutaneous fistula is a rare complication of uterine surgery. All published cases have been surgically treated with hysterectomy and excision of the fistulous tract. We report a case of uterocutaneous fistula that was successfully treated with Gonadotropin-Releasing Hormone Agonist administration. CASE: A 25-year-old woman reported bloody discharge during her periods from a previous Pfannenstiel incision. A fistulous tract leading from the incision scar to the uterus was diagnosed. Leuprolide acetate depot was administered twice subcutaneously at a dose of 11.25 mg. The fistulous tract closed spontaneously, and the patient was symptom free thereafter. CONCLUSION: Medical treatment with Gonadotropin-Releasing Hormone Agonists should be considered before resorting to surgery for treatment of uterocutaneous fistulae.

Mamoru Morikawa - One of the best experts on this subject based on the ideXlab platform.

  • effect of gonadotropin releasing Hormone Agonist on a uterine arteriovenous malformation
    Obstetrics & Gynecology, 2006
    Co-Authors: Mamoru Morikawa, Takashi Yamada, Hideto Yamada, Hisanori Minakami
    Abstract:

    BACKGROUND: The effect of Gonadotropin-Releasing Hormone Agonist (GnRHa) on uterine arteriovenous malformations (AVM) is not well known. CASE: A 37-year-old woman with a previous cesarean was diagnosed as having a uterine AVM after a spontaneous abortion with massive vaginal bleeding. The AVM decreased in size from 5.1 x 3.8 cm to 1.4 x 1.0 cm after 6 months of therapy with a GnRHa. Uterine artery embolization conducted after the GnRH therapy resulted in complete disappearance of the AVM. The patient's menstrual cycles and ovulation resumed 3 months after uterine artery embolization. CONCLUSION: Gonadotropin-Releasing Hormone Agonist therapy reduced the size of the uterine AVM. Thus, GnRHa therapy may be useful for uterine AVM in situations where uterine artery embolization must be postponed.

  • Effect of Gonadotropin-Releasing Hormone Agonist on a uterine arteriovenous malformation.
    Obstetrics and gynecology, 2006
    Co-Authors: Mamoru Morikawa, Takashi Yamada, Hideto Yamada, Hisanori Minakami
    Abstract:

    The effect of Gonadotropin-Releasing Hormone Agonist (GnRHa) on uterine arteriovenous malformations (AVM) is not well known. A 37-year-old woman with a previous cesarean was diagnosed as having a uterine AVM after a spontaneous abortion with massive vaginal bleeding. The AVM decreased in size from 5.1 x 3.8 cm to 1.4 x 1.0 cm after 6 months of therapy with a GnRHa. Uterine artery embolization conducted after the GnRH therapy resulted in complete disappearance of the AVM. The patient's menstrual cycles and ovulation resumed 3 months after uterine artery embolization. Gonadotropin-Releasing Hormone Agonist therapy reduced the size of the uterine AVM. Thus, GnRHa therapy may be useful for uterine AVM in situations where uterine artery embolization must be postponed.

Ayse Seyhan - One of the best experts on this subject based on the ideXlab platform.

  • Medical treatment of uterocutaneous fistula with Gonadotropin-Releasing Hormone Agonist administration.
    Obstetrics and gynecology, 2008
    Co-Authors: Ayse Seyhan, Baris Ata, Bilhan Sidal, Bulent Urman
    Abstract:

    Uterocutaneous fistula is a rare complication of uterine surgery. All published cases have been surgically treated with hysterectomy and excision of the fistulous tract. We report a case of uterocutaneous fistula that was successfully treated with Gonadotropin-Releasing Hormone Agonist administration. A 25-year-old woman reported bloody discharge during her periods from a previous Pfannenstiel incision. A fistulous tract leading from the incision scar to the uterus was diagnosed. Leuprolide acetate depot was administered twice subcutaneously at a dose of 11.25 mg. The fistulous tract closed spontaneously, and the patient was symptom free thereafter. Medical treatment with Gonadotropin-Releasing Hormone Agonists should be considered before resorting to surgery for treatment of uterocutaneous fistulae.

  • Medical treatment of uterocutaneous fistula with Gonadotropin-Releasing Hormone Agonist administration.
    Obstetrics & Gynecology, 2008
    Co-Authors: Ayse Seyhan, Baris Ata, Bilhan Sidal, Bulent Urman
    Abstract:

    BACKGROUND: Uterocutaneous fistula is a rare complication of uterine surgery. All published cases have been surgically treated with hysterectomy and excision of the fistulous tract. We report a case of uterocutaneous fistula that was successfully treated with Gonadotropin-Releasing Hormone Agonist administration. CASE: A 25-year-old woman reported bloody discharge during her periods from a previous Pfannenstiel incision. A fistulous tract leading from the incision scar to the uterus was diagnosed. Leuprolide acetate depot was administered twice subcutaneously at a dose of 11.25 mg. The fistulous tract closed spontaneously, and the patient was symptom free thereafter. CONCLUSION: Medical treatment with Gonadotropin-Releasing Hormone Agonists should be considered before resorting to surgery for treatment of uterocutaneous fistulae.

Kenichi Tanaka - One of the best experts on this subject based on the ideXlab platform.

  • resolution of uterine arteriovenous malformation and successful pregnancy after treatment with a gonadotropin releasing Hormone Agonist
    Obstetrics & Gynecology, 2011
    Co-Authors: Taro Nonaka, Tetsuro Yahata, Katsunori Kashima, Kenichi Tanaka
    Abstract:

    Background Uterine arteriovenous malformations are a rare and potentially life-threatening condition. Medical therapy has not been popular because of the propensity for excessive bleeding in the patient. As a result, the effect of Gonadotropin-Releasing Hormone (Gn-RH) Agonists on uterine arteriovenous malformations has not been established. Case A 30-year-old patient presented with persistent vaginal bleeding. Based on the color Doppler ultrasound and magnetic resonance imaging findings, a uterine arteriovenous malformation was diagnosed. Because initial treatment with methylergonovine maleate was unsuccessful, the patient was treated with Gn-RH Agonists. The lesion completely disappeared after 6 months of Gn-RH Agonist treatment. Five months after the completion of Gn-RH Agonist therapy, the patient conceived spontaneously and successfully completed a normal pregnancy. The patient has remained free from recurrence of the lesion. Conclusion Gonadotropin-Releasing Hormone Agonist therapy has the potential to be a conservative treatment modality for uterine arteriovenous malformations in hemodynamically stable patients.